It's around 10-15% for the whole drug I-III flow (13.8% according to [1]), but that varies dramatically based on therapeutic area. On the order of a third of infectious disease vaccines might be approved but only maybe 5% of oncology therapies because the latter often have a different standard for approval so it's cheaper to run trials.

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC6409418/

▲

amelius 2 hours ago | parent [-]

That's interesting, but I was talking about the success rate of someone with a terminal illness going the clinical trial route. Sorry, I now see that my question was not so precise.

	▲	throwup238 2 hours ago \| parent [-]
		For cancer, it doesn't seem to impact survival odds at all [1]. In other fields it may improve metrics a small bit but that's largely because in clinical trial patient selection, they're very careful to exclude anyone with an even remotely confounding factor (like weight/BMI). [1] https://www.science.org/content/article/joining-cancer-trial...